Santa Monica, CA, July 11, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company
developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion
electrophysiology (EP) marketplace, today announced that the research poster entitled “Unipolar Intracardiac Signal Morphology as a
Parameter for Catheter Contact Evaluation” will be presented on Wednesday, July 18 from 17:15 – 19 in Exhibit Hall 2 during the
40th International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2018).
BioSig’s paper discusses a very significant problem common for current electrophysiology (EP) studies. Optimal contact between
catheter tip and myocardial tissue is very important as it affects both the accuracy of cardiac maps and the efficacy of ablation
energy delivery. Our findings suggest that the morphology of a unipolar signal obtained by using our PURE EP(TM) System can provide
incremental information in proper contact evaluation.
“BioSig continues to collaborate with the best scientists in the electrophysiology field and strives toward advancing the
understanding of treatments for complex arrhythmias. These findings can potentially lead to more effective ablation strategies, and
ultimately, and more importantly, better outcomes for patients,” commented Kenneth L. Londoner, Chairman and CEO of BioSig
Technologies, Inc.
About EMBC 2018
The IEEE Engineering in Medicine and Biology Society is hosting its 40th International Engineering in Medicine and Biology
Conference in Honolulu, Hawaii from July 17-21, 2018 at the Hawaii Convention Center. The theme of the meeting is “Learning from
the Past, Looking to the Future”, inspired by the 40th anniversary of the world’s largest international biomedical engineering
meeting. The conference will highlight plenary keynotes from leading industrial and academic scientists and cover cutting-edge
research and innovation in biomedical engineering, healthcare technology R&D, translational clinical research, technology
transfer and entrepreneurship, and biomedical engineering education.
About IEEE
The Institute of Electrical and Electronics Engineers (IEEE) is world's largest association of technical professionals with more
than 420,000 members in over 160 countries around the world. Its objectives are the educational and technical advancement of
electrical and electronic engineering, telecommunications, computer engineering and allied disciplines.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to
improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has
been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to
assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates
and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly
arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and
is working toward FDA 510(k) clearance for the PURE EP(TM) System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Registration Statement on Form S-1
(File No. 333-223298), as declared effective on March 26, 2018, its Annual Report on Form 10-K/A filed with the SEC on March
26, 2018 and its Quarterly Report on Form 10-Q as filed with the SEC on May 4, 2018. Investors and security holders are urged to
read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
